Epilepsy device maker NeuroSigma files for a $50 million IPO

Shutterstock photo

NeuroSigma, which develops electrical devices used to treat drug-resistant epilepsy and depression, filed on Tuesday with the SEC to raise up to $50 million in an initial public offering. The company is in pivotal trials to have its bioelectronic products approved in the US, and has received marketing approval in Australia, Canada and the EU.

Recent epilepsy IPOs include biotechs Marinus Pharmaceuticals ( MRNS ) and Sage Therapeutics ( SAGE ).

The Los Angeles, CA-based company, which was founded in 2008 and booked $52,000 in sales for the 12 months ended June 30, 2014, plans to list on the NASDAQ under the symbol NSIG. NeuroSigma initially filed confidentially on November 27, 2013. Jefferies is the sole bookrunner on the deal. No pricing terms were disclosed.

The article Epilepsy device maker NeuroSigma files for a $50 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs
Referenced Symbols: MRNS , SAGE

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?